Image source: The Motley Fool.
Adamas Pharmaceuticals Inc (ADMS)
Q2Â 2019 Earnings Call
Aug. 08, 2019, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day, ladies and gentlemen, and welcome to the Adamas Pharmaceuticals Second Quarter 2019 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions for how to participate will follow at that time. [Operator Instructions].
I would now like to turn the call over to Peter Vozzo from Westwicke Partners of Investor Relations for our Adamas Pharmaceuticals. Please go ahead.
Peter Vozzo -- Managing Director
Thank you, Jimmy, and good afternoon, everyone. Before we begin, I would like to remind everyone that this call will contain forward-looking statements which are subject to risks and uncertainties. Any statements regarding future events, results or expectations are forward-looking statements. Please note that these forward-looking statements reflect our opinions only as the date of this call. We undertake no obligation to revise or update these forward looking statements in light of new information or future events. Information concerning factors that could cause actual results to differ materially from those contained in or implied by such forward looking statements are discussed in greater detail in our form 10-Q filed today with the SEC.
I will now turn the call over to Greg Went, Chief Executive Officer.
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
Thank you, Peter, and good afternoon, everyone. Thank you for joining us today. I'm here with Vijay Shreedhar, our new Chief Commercial Officer, Dr. Rajiv Patni, our Chief Medical Officer and Alf Merriweather, our Chief Financial Officer.
Our two priorities for Adamas in 2019 are driving toward commercial success by broadening and deepening GOCOVRI's use in patients with Parkinson's disease with dyskinesia and delivering top-line Phase 3 data for an additional indication for GOCOVRI in multiple sclerosis patients with walking impairment.
Turning to our second quarter total GOCOVRI paid prescriptions, which excludes patients from the free trial program rose to 6,160, up about 6% from Q 1, 2019. This growth continues to be driven by patients refilling GOCOVRI. New patient starts were up about 2%, to 740, primarily from patients using the new free trial program. While it's early days for this program, the initial conversion to paid prescriptions is running at 40% to 50%. We look to improve utilization with better promotion of the program with our physicians and increase conversion by improving operational efficiencies with the process.
Patients refilling their prescriptions remains a key driver of GOCOVRI's growth and provides a strong foundation for our future commercial initiatives. Persistence remains very solid, with 55% to 60% of patients remaining on GOCOVRI at 6 months and 45% to 50% at 12 months. Maintaining this level of persistence from 6 to 12 months is a strong indicator of the value that GOCOVRI is bringing to patients and these numbers are compelling.
For context, Rasagiline, a commonly used and widely considered, well tolerated adjunctive treatment for Parkinson's disease, showed persistence rates of 49% and 37%, at 6 and 12 months respectively, in our recently presented poster.
Turning now to our development programs, our INROADS Phase 3 trial completed enrollment this quarter and is set to read out at the end of 2019. Rajiv will walk you through the final enrollment details later on this call.
It's important to note that this is an already established market. Today, we believe there are approximately 270,000 multiple sclerosis patients with moderate to severe walking impairment. Out of those patients approximately 50,000 are receiving ongoing treatment with dalfampridine. Another 100,000 have tried dalfampridine and discontinued it, and the remaining a 120,000 are dalfampridine naive. We anticipate that our initial commercial focus will be on those who've tried and discontinued dalfampridine and we look forward to seeing the top-line data from our INROADS study prior to finalizing that strategy.
Now, I am pleased to introduce Vijay Shreedhar, who joined us last quarter to lead our commercial efforts. Vijay is a proven commercial leader who has grown multiple brands across multiple therapeutic areas of Amgen over the past decade. What is particularly impressive about Vijay is a strong scientific and broad business background. He has demonstrated success at Amgen in roles spanning the commercial continuum, from sales to marketing to brand management. Vijay has used his skills to both launch and realize the value of some of Amgen's key brands.
I am delighted to have Vijay join us to lead our commercial team and help drive us forward. Over to you, Vijay.
Vijay Shreedhar -- Chief Commercial Officer
Thank you, Greg. And good afternoon, everyone. It is great to be speaking with you today. In the last two months or so that I've been at Adamas, I have been in listening and learning mode, interacting with a range of key stakeholders to develop a deep understanding of our business. I have visited top movement disorder centers and neurologists to observe practice considerations, attended the International Association of Parkinsonism and Related Disorders Congress to meet with thought leaders and gather insights from the leading healthcare providers on our speakers bureau.
Additionally, I have visited our specialty pharmacy partner to assess the operational elements of our fulfillment and distribution process. Internally, I have spoken individually and collectively to our entire sales and broader commercial teams to collect learnings and assess our organizational needs to fully unlock the commercial potential of GOCOVRI . These interactions have confirmed the optimism and excitement for the potential of GOCOVRI, which drew me to Adamas in the first place.
I have been impressed to hear from many of the physicians and nurses, who have clinical experience with GOCOVRI about the positive impact that the drug has on patients and caregivers lives. These healthcare practitioners see GOCOVRI as a drug with proven clinical data and a differentiated clinical profile, as a result of these data. The recently published individual patient level analyses of the diary data from our pivotal Phase 3 program, corroborate the prescriber feedback to me, that GOCOVRI represents a paradigm shift, because of its concomitant effect on dyskinesia and OFF. Many of the clinicians, I have interacted with, have positive patients stories and are excited about the prospects for GOCOVRI moving forward. In short, the clinicians I've spoken with, believe the drug works very well.
My interactions with our sales force, have shown me both their commitment and passion to improve the lives of people affected by Parkinson's disease, and the depth and relevance of their experience in neurology and with previous launches.
However, my interactions have also highlighted that we have work to do. There are three key areas, where I will focus intensively in the weeks and months ahead. First, we need to do a better job in educating healthcare practitioners to recognize the disruptive impact of dyskinesia, its relationship to OFF, and its impact on the effective treatment of Parkinson's disease. While prevalent in patients treated would leave levodopa, dyskinesia is still relatively poorly understood or appreciated by both prescribers and patients. It is often confused with tremors and the impact that it may have on many aspects of a patient's daily life is not effectively highlighted. Educating healthcare practitioners on these aspects, and on how to systematically identify appropriate patients for consideration of GOCOVRI therapy offers an opportunity for enhancing patient care.
Second, based on my recent observations, there is an opportunity to improve our operational effectiveness in the fulfillment process. From the moment when a physician sends in a treatment form to when a patient gets the drug, I have noted some level of frustration among prescribers and we are working actively to address this, and to improve the customer centricity of our overall fulfillment process. To ensure that we create one that is simple, reliable and transparent.
Third, we need to better educate a wider audience about our 28-day free trial program, which we hope will expand trial of the drug among non-adopters. We will look at every element of the program in order to make progress on this front.
While I'm initially focused on these three areas, I continue to examine every element of our strategy and execution, and I look forward to sharing additional details about our strategic and operational plans in future calls. All of the interactions that I have described have deepened my belief in the opportunity that initially drew me to Adamas. I have heard how GOCOVRI has a significant impact on patients with Parkinson's disease and have come to appreciate the impact it may have over time in other indications.
I'm particularly excited about the first of these other indications in MS walking and will turn the call over to Rajiv to discuss our progress.
Rajiv Patni -- Chief Medical Officer
Thanks, Vijay. I'm happy to report that enrollment is complete in our INROADS Phase 3 trial of ADS-5102 in MS patients with walking impairment. This is a significant milestone in our development program. We are on track to report top-line data in late Q4, 2019. This study is a three arm randomized, double-blind placebo controlled study of two dose levels of ADS-5102. The primary efficacy endpoint is the proportion of responders in each treatment group. A responder is defined as a patient who experienced at least a 20% increase in walking speed from baseline, as measured by the timed 25 foot walk test.
Key secondary endpoints include the mean change from baseline in walking speed, the Timed Up and Go or TUG and the 2-minute walk test. The baseline demographics are noteworthy, because these data provide a snapshot into the real world effectiveness of dalfampridine. Approximately, 50% of enrolled patients had received dalfampridine in the past and discontinued. This represents the dalfampridine discontinued subgroup.
The other 50% of enrolled patients represent the dalfampridine naive subgroup. In the dalfampridine discontinued subgroup, the reason for discontinuation prior to study entry was limited efficacy in 48% and adverse events in 21%. Since the dalfampridine discontinued and naive subgroups are each reasonably sized, pre-specified analyses will provide an opportunity to characterize the treatment effect of ADS-5102 in both subgroups. Our thesis remains that the treatment effect will be consistent irrespective of prior dalfampridine use.
If the Phase 3 data from INROADS supports our thesis, and ADS-5102 has the potential to be a treatment option for the breadth of the MS population with walking impairment. We believe the initial unmet medical need is in patients who discontinued dalfampridine in the past due to limited efficacy and/or in tolerability. Our current estimate of the size of this population today is about 100,000 patients. We look forward to the read out of this trial late in fourth quarter of 2019. If successful, we expect to initiate a second pivotal study to support approval. If approved on this pathway and timeline, we would plan to launch GOCOVRI for this new indication in 2022.
I will now turn the call over to Alf.
Alfred Merriweather -- Chief Financial Officer
Thanks, Rajiv. In the second quarter of 2019, we recorded GOCOVRI product sales of $12.7 million. This was recorded on the sell-in method with revenue recognized typically upon delivery to our specialty pharmacy. The approximate number of total paid prescriptions was 6,160 in the second quarter, compared to 5,820 in the first quarter of 2019, about 6% higher than the prior quarter.
Gross to net was consistent with the prior quarter and our commentary on the last call. Regarding our overall operating results.
Net loss for the quarter was $24.9 million or a loss of $0.90 per share compared to a loss of $34 million or $1.26 per share in the second quarter of 2018.
Cash and investments as of June 30, 2019 were $169 million, compared to $211 million at December 31, 2018. Overall, cash burn for the quarter was consistent with prior quarters at approximately $22 million.
Let me now turn the call back over to Greg.
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
Thanks, Alf. Thanks, Rajiv. And thanks, Vijay. I want to thank the whole Adamas team for their continued commitment to building a sustainable business based upon the discovery, development and commercialization of our time dependent medicines. As we reported in the press release earlier today, we announced that Alf will retire on December 31, 2019. He will be succeeded by Chris Prentiss on November 1, the Company's current Senior Vice President of Finance and Chief Accounting Officer. I am deeply appreciative you, Alf, for your contribution to Adamas' growth and your role in mentoring Chris as your successor. I also appreciate your continued involvement to ensure a smooth transition. Many of you will already know Chris from our interactions with you on the road. He has been a leader in our finance organization since he joined us in early 2015 and has played an integral role in building our financial infrastructure. Finally, I'm thrilled to have the Vijay's leadership as he reshapes and focuses our commercial efforts to better drive the adoption of GOCOVRI by physicians and patients. I am also excited for our INROADS top-line results in late Q4, which, if successful we expect it'll add significant potential to GOCOVRI.
And with that I'd like to open up the line for questions. Operator?
Questions and Answers:
Operator
Thank you. [Operator Instructions] Our first question comes from Marc Goodman with SVB Leerink. Your line is now open.
Rudy Li -- SVB Leerink -- Analyst
Hi. It is Rudy on the line for Marc. So I'm just wondering -- first question is, how the physician and patient feedback so far with free drug program, have noticed any notable changes on the treatment landscape, on the dynamics? Second question is, we planned for the patient awareness campaign in June, I'm just wondering, can you provide more color on that program? Thanks.
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
Thank you very much for the question. Vijay, you want to tackle both of those?
Vijay Shreedhar -- Chief Commercial Officer
Sure. Let me begin with the free trial program. The program is being perceived right now, in terms of feedback, as being one of the most generous among all of the peer set. It is a 28-day free trial program. The adoption among current users of GOCOVRI has been very robust. And as I said, our goal moving forward is to expand knowledge and awareness of that program and trial of that program among non-adopters and new patient types.
In terms of your second question. We have initiated a program called the Go Getter patient education Program. It is currently in market. It was fielded toward the end of May, beginning of June. It is just a little early to speak to what the impact of that program is, but we'll keep you posted in future calls.
Rudy Li -- SVB Leerink -- Analyst
Thanks. That's very helpful.
Operator
Thank you. Our next question comes from David Amsellem with Piper Jaffray. Your line is now open.
David Amsellem -- Piper Jaffray -- Analyst
Thanks. So, just a couple. First on commercial consideration for GOCOVRI in MS. Are you expecting -- this is really for Vijay, are you expecting a step through toward dalfampridine in order to gain access to the product? And I realize that you don't have the data, but talk about the -- how restrictive you think the payer landscape would be vis-a-vis dalfampridine? A follow on, number two, would you consider partnering with another company for the commercial launch or are you completely wedded to launching it on your own? And if so, how many reps are you going to add to support the launch in MS gait? Thanks.
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
Vijay?
Vijay Shreedhar -- Chief Commercial Officer
Yes. So, two-part question, I see. So the first question in terms of MS itself, it all depends on the clinical profile of the drug and what the clinical studies show us and what that readout is. We all eagerly anticipate toward the end of this year. What I will comment on in the MS market is, was commented on in the prepared remarks is, a lot of learnings for us from where we are in the PD market and what we can apply to in the MS market. Now it is a well-established market for MS walking. It is a market which has seen specialty neurology drugs for a long period of time. The patient demographics are younger, more motivated to seek help and to proactively talk to their physicians about new treatment options. So we expect a different and more active dynamic for how that drug launches in that market.
To your second question, we have done some preliminary analysis of where the account concentration and physician prescriber concentration is for MS, it does remain highly concentrated. So, we'll keep you posted about our plans for the sales force. But currently, I believe we are right-sized for what we need to do.
David Amsellem -- Piper Jaffray -- Analyst
Okay. Thank you.
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
Thanks, David.
Operator
Thank you. And our next question comes from Tim Lugo with William Blair. Your line is now open.
Myles Minter -- William Blair -- Analyst
Hi. This is Myles on for Tim. Thanks for taking the questions. Just the first one on your 40% to 50% conversion rate for the free drug program, I am wondering how many of those patients actually experienced a neuropsych adverse event? And whether or not, there is obviously more conversion from free drug to paid drug in patients that happen to have that bad experience? And then secondly, just in terms of the INROADS trial and now assessing dalfampridine discontinuations and native treatment, was that trial when you responded was it already powered to view those two groups on and off drug on your primary endpoint there and what are your pairing assumptions in general? Thanks.
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
Vijay, you want to go first again?
Vijay Shreedhar -- Chief Commercial Officer
So, we have done an analysis of patients who received drug through the free trial program in order to understand where the gaps were in them converting to maintenance scripts. The vast majority of patients actually drop-off because of operational considerations, right? There are prior authorizations that are still in process. There are steps that a physician's office needs to complete. There are steps that a patient themselves need to complete. That's where we believe we can have the most impact, which is why one of the focus areas that I articulated, in terms of fulfillment, focuses on the operational effectiveness to make it simpler, and more transparent and reliable. And actually the AEs are not one of the big reasons why they drop off as far as we've seen in our initial analysis. Let me pass on to Rajiv.
Rajiv Patni -- Chief Medical Officer
And onto the INROADS stay design, as I shared in my prepared remarks, the trial based on FDA feedback at the end of Phase 2 meeting was powered to compare active to placebo, a assumption of 33% inactive versus 20% placebo. And equally importantly is that each subgroup I commented on is reasonably sized, permitting us to characterize the effect on those patients who are treated with dalfampridine in the past versus who were not.
Myles Minter -- William Blair -- Analyst
Beautiful. Thanks for the clarification and congratulations, Alf.
Alfred Merriweather -- Chief Financial Officer
Thank you.
Operator
Thank you. And our next question comes from Ken Cacciatore with Cowen and Company. Your line is now open.
Ken Cacciatore -- Cowen and Company -- Analyst
Thanks, guys, for the questions. Vijay, I know you're new in going through all the different parts of the operation, but just wondering your view of OSMOLEX and its implications to the launch and is there any way in which we can avoid them or somehow have that impact mitigated? And then secondly, can you get into a little bit deeper into this fulfillment issue with these number of patients that you're talking about, new patients starting? It seems as if you could really give a white-glove service almost on an individual level to get them going.
So just confused as to what is happening that somehow with this view of patients we're losing not properly processing paperwork and getting the drug to them. And then lastly, can you just talk about the co-pay and the charities that are available to help? Any sense of what's going on with those? And is the co-payment and that issue causing some problems as well? Thank you.
Vijay Shreedhar -- Chief Commercial Officer
Sure. So let me begin with the first part of your question, which was with regard to OSMOLEX. Here's what I've learned in my listening tour the last couple of months. As I said in my prepared remarks, GOCOVRI really stands out as a differentiated drug, in this space because of the clinical profile which has been demonstrated through a couple of clinical trials, right. So the only drug to have clinical efficacy demonstration in a large clinical trial, both on the dyskinesia side and secondarily on the OFF side and also in recent post-hoc analyses to show the increase in continuous on-time the reduction of disruptive episodes in a patient's day, so really a remarkable clinical profile is how physicians characterize it to me. So I think the other competitors are in the market, but we don't believe that they are making as many inroads or having a significant impact on our presence in the marketplace. So that's your question one.
In terms of fulfillment, which was your second question, I think we are looking at various aspects of the process, the steps in the process, the complexity of the process, the lack of -- or I'd rather frame it as a white space that exists between a physician spending in a treatment form and then finally getting confirmation that their patient is on drugs. There are a lot of elements during this process where we could potentially look and improve our services and that's where our focus is. So. The option that you proposed is on the table and we're looking at all options.
The third question you had was about co-pay and charities. I presume you're referring to foundations and where assistance to patients is being offered. We are continuing to see that patients are able to access our drug both on the commercial side and on the Medicare side, and we're continuing to see that happen. I think you raised a larger question in terms of cost of some specialty drugs. And we're looking at the various options to continue to drive access.
Ken Cacciatore -- Cowen and Company -- Analyst
Thank you
Operator
Thank you. And our next question comes from Tazeen Ahmad with Bank of America. Your line is now open.
Bill -- Bank of America -- Analyst
Hi, this is Bill on for Tazeen. So I have two questions. First of all, GOCOVRI for LID has a pretty clear story around the time-dependent biology where you want to wake up with therapeutic levels on-board to avoid the morning off. How does the same time dependent in biology translate into MS walking where the diurnal pattern isn't as clear? And then for Vijay, you mentioned expanding the free drug program and getting more non-adopters to, take it up. On your listening tour, what have you heard from the non-adopters as their primary reason for not adopting GOCOVRI at this point? Thanks.
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
Hey, Bill. It's Greg, thanks for the question. I'll take the first one and then I'll see if Rajiv wants to add to it. You know I think the reason why folks are familiar with the time-dependent hypothesis around dyskinesia and often Parkinson's is because we're well beyond our Phase 3 program where we've demonstrated it and we've talked about the underlying science to a much greater deal. In the MS area we began with a very similar understanding of the pathways that are involved in allowing people to move. We understood how those were coupled to our circadian patterns that crucially drove the hypothesis and we proved that program out, beginning with pre-clinical studies, moving it into animal models and moving it into human proof-of-concept. So, as we look and see the data coming out here and have more confidence from completed Phase 3 programs we'll begin to tell that story, the basic science story, and the symptom coverage story in a more public forum.
Rajiv Patni -- Chief Medical Officer
And the only thing I would add, Greg is, encourage you to see our poster from AAN where we began explaining to the community the time dependency of MS walking impairment for the first time.
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
And Vijay, yeah the have a second one for you.
Vijay Shreedhar -- Chief Commercial Officer
Sure. I think that the question was about the reasons that are stated in terms of my listening tour in terms of non-adopters. Right? They really boil down to two areas. I think the first is what I alluded to in terms of the opportunity with educating physicians because I think what I've heard so far is confusion around dyskinesia, how does it manifest? Is it bothersome? That conversation that happens with patients, is that enough on a once every 3 to 6-month basis to identify the patients for consideration. The relationship between dyskinesia and OFF and I think when they learn about our clinical profile more, that shows us as an opportunity for us to really talk about GOCOVRI and get them along the continuum. The other reason that they talk about most often is cost and perceptions of cost. And as we share some of our real data from the last year-and-a-half of experience, that seems to help them as well in terms of making that choice.
Bill -- Bank of America -- Analyst
Thank you.
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
Thanks.
Operator
Thank you. And our next question comes from Serge Belanger with Needham. Your line is now open.
Serge Belanger -- Needham -- Analyst
Hi, good afternoon. A couple questions for me. First on the payer landscape, how satisfied are you with the current landscape? What else needs to be done there? And do you think it'd be a driver for sales in the second half of the year?
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
Vijay, you want to take that?
Vijay Shreedhar -- Chief Commercial Officer
Sure. So, let me sate upfront, right, we are committed to making GOCOVRI as broadly available to patients as possible. And we continue to see from what we have tracked in the first part of 2019 that prescriptions are being paid through the prior auth mechanism and coupled with the medical necessity for both commercial and Medicare plans. We've seen no significant change in access in the first part of 2019. So I want to make sure that that folks you are aware. We continue to evaluate the payer landscape and we evaluate contracting as a means to drive access to simplify the prior auth process, to reduce physician burden in terms of process. But in the meantime, I think the greater area of focus for us, would be educating them about dyskinesia and the value of GOCOVRI there. The real simplification of our fulfillment process to make it simpler for the physicians practice, and really making them aware of the free trial program. Even trial the drug, and those are the three areas we can focus on.
Serge Belanger -- Needham -- Analyst
Okay. And just looking at my notes, in terms of new patients, that number has been in the 700 range for the last few quarters. Should we expect that to move up as the free program gets a little bit more implemented?
Vijay Shreedhar -- Chief Commercial Officer
So I would say, are we satisfied with our number? No. We are continuously looking at ways for us to educate all stakeholders and improve that number. I think it's a little early for me to speak to when that turnaround will happen, but that is definitely the goal is to get us on a trajectory of robust growth in that number.
Serge Belanger -- Needham -- Analyst
Thanks. All right. Also I want to offer my congrats to Alf.
Alfred Merriweather -- Chief Financial Officer
Thank you.
Operator
Thank you. [Operator Instruction] Our next question comes from Ram Selvaraju with H.C. Wainwright. Your line is now open.
Ram Selvaraju -- H.C. Wainwright -- Analyst
Thanks very much for taking my questions. I just wanted to get some additional clarity on the 28-day sampling program. Do you have a sense of how long you expect to keep that in place? If that's going to be sort of core component of the sales and marketing strategy for GOCOVRI indefinitely? Or if you have a plan to sort of eventually phase it out or change it in any way? And if so, what might the changes be that you would make?
And then I also wanted to ask if you're seeing any potential promotional impact from OSMOLEX ER? Obviously that's been kind of around for a while, but I don't know whether you're actually seeing any promotional activities of that product coming up against you in the marketplace? If you could provide some color on that, that would be helpful.
Vijay Shreedhar -- Chief Commercial Officer
To your latter question, your second question, the answer is, no. To the first question, I would say in terms of the free trial program, the current plan is --in the current format, to remind folks it's a 28-day free trial, where the drug is shipped directly to the patient, in that format we plan to continue it through the end of the year, as we have previously announced. But part of what I'm looking at right now is all of the various options open to us in addition to looking at the key metrics that come off of the current program. We're looking and evaluating at various options, one obvious option is, do we with one of the other ways of getting a free trial to a patient? So we are evaluating all options, and I'll keep you posted in the coming quarters.
Ram Selvaraju -- H.C. Wainwright -- Analyst
Okay, and then just -- do you have any further updates at this time on the status of the Qui tam lawsuit?
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
I'll take that. No, we don't and we don't, as you imagine, we don't comment on ongoing litigation.
Ram Selvaraju -- H.C. Wainwright -- Analyst
Okay. Thank you.
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
Thanks, Ram.
Operator
Thank you and I'm showing no further questions in the queue at this time. I'd like to turn the call back to Greg Went for any closing remarks.
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
So listen, I want to thank everyone for participating today at the end of the summer. And we look forward to seeing you at upcoming conferences and meetings that we have ahead of our next earnings call. Thanks so much today and again, my thanks again to Al for his service here, the team and as well as looking forward to having Chris on the next call. Thanks very much.
Operator
[Operator Closing Remarks]
Duration: 35 minutes
Call participants:
Peter Vozzo -- Managing Director
Gregory Went -- Co-Founder, Chairman & Chief Executive Officer
Vijay Shreedhar -- Chief Commercial Officer
Rajiv Patni -- Chief Medical Officer
Alfred Merriweather -- Chief Financial Officer
Rudy Li -- SVB Leerink -- Analyst
David Amsellem -- Piper Jaffray -- Analyst
Myles Minter -- William Blair -- Analyst
Ken Cacciatore -- Cowen and Company -- Analyst
Bill -- Bank of America -- Analyst
Serge Belanger -- Needham -- Analyst
Ram Selvaraju -- H.C. Wainwright -- Analyst
Transcript powered by AlphaStreet
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
